Switch to:
More From Other Websites
XenoPort Announces Pricing of $100 Million 2.50% Convertible Senior Notes due 2022 Jan 29 2015
9:01 am Xenoport announces the pricing of $100 mln aggregate principal amount of 2.50% Convertible... Jan 29 2015
XenoPort Announces Pricing of $100 Million 2.50% Convertible Senior Notes due 2022 Jan 29 2015
XENOPORT INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Jan 28 2015
XenoPort Announces Proposed Offering of $100 Million Convertible Senior Notes due 2022 Jan 28 2015
XENOPORT INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Jan 16 2015
Xenoport (XNPT) Shares March Higher, Can It Continue? - Tale of the Tape Jan 15 2015
XENOPORT INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jan 12 2015
XenoPort Provides Highlights of HORIZANT Prescription Trends and Update on Development for Alcohol... Jan 11 2015
Stock Pops & Drops: SCTY, ARCP, XNPT & GG Dec 30 2014
[video]Stocks Fall in Light Trading as Oil and Greece Weigh on Markets Dec 30 2014
Civeo shares plunge; NeuroDerm jumps Dec 30 2014
XENOPORT INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Nov 26 2014
Surging Earnings Estimates Signal Good News for Xenoport (XNPT) Nov 18 2014
XENOPORT INC Financials Nov 14 2014
Can the Uptrend Continue for XenoPort (XNPT)? Nov 11 2014
10-Q for XenoPort, Inc. Nov 07 2014
XenoPort to Present at the Credit Suisse Healthcare Conference Nov 06 2014
XenoPort to Present at the Credit Suisse Healthcare Conference Nov 06 2014
XENOPORT INC Files SEC form 10-Q, Quarterly Report Nov 05 2014


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK